Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Kidgell
A E
AE
Clinical Research (Infection and Oncology) Glaxo Group Research Ltd., Greenford, Middlesex, U.K.
Butcher
M E
ME
Brown
G W
GW
D000932:Antiemetics / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D017829:Granisetron; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D007191:Indazoles / Q000737:chemistry / Q000627:therapeutic use; D007211:Indoles / Q000737:chemistry / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy; D017294:Ondansetron; D011832:Radiation Injuries / Q000188:drug therapy; D011878:Radiotherapy / Q000009:adverse effects; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D000077526:Tropisetron; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D002945:Cisplatin; D017829:Granisetron; D007093:Imidazoles; D007191:Indazoles; D007211:Indoles; D017294:Ondansetron; D012702:Serotonin Antagonists; D000077526:Tropisetron